Sai Life Sciences (NSE:SAILIFE, BOM:544306) has begun commercial operations of the second phase of the production block with 91 kiloliter of capacity at its Bidar facility in Karnataka, India.
This is the second and final phase of the unit's overall capacity addition of 195 kiloliter, according to a Friday filing to the Indian stock exchanges.
With this, the combined capacity of Unit IV Bidar facility will be 640 kiloliter, which will supply to registered starting materials (RSM), intermediates, and active pharmaceutical ingredients (APIs) for clinical and commercial purposes.
The company's shares were up nearly 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.